ArticleMolecular medicine reports2017
Differences in cell death and cell cycle following fucoidan treatment in high-density HT-29 colon cancer cells.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Selective antimicrobial potential of fucoidans against the pathogenFrontiers in microbiology · 2026Article
- Microbial exopolysaccharides as a sustainable food ingredient and their health benefits.Food science and biotechnology · 2025Review
- Article
- Antioxidant and anticancer properties of fucoidan isolated from Saccharina Japonica brown algae.Scientific reports · 2025Article
- Potential therapeutic target for polysaccharide inhibition of colon cancer progression.Frontiers in medicine · 2023Review
- Marine Bioactive Compounds Derived from Macroalgae as New Potential Players in Drug Delivery Systems: A Review.Pharmaceutics · 2022Review
- Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted fromJournal of agricultural and food chemistry · 2022Article
- Preparation of Low-Molecular-Weight Fucoidan with Anticoagulant Activity by Photocatalytic Degradation Method.Foods (Basel, Switzerland) · 2022Article
- Dichloromethane fractions ofMolecular medicine reports · 2022Article
- Bioactive Carbohydrate Polymers-Between Myth and Reality.Molecules (Basel, Switzerland) · 2021Review
- Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer.International journal of molecular sciences · 2021Article
- Fucoidan Inhibits the Progression of Hepatocellular CarcinomaFrontiers in oncology · 2021Article
- Bioactive Metabolites from Marine Algae as Potent Pharmacophores against Oxidative Stress-Associated Human Diseases: A Comprehensive Review.Molecules (Basel, Switzerland) · 2020Review
- Marine-Derived Surface Active Agents: Health-Promoting Properties and Blue Biotechnology-Based Applications.Biomolecules · 2020Review
- Brown Seaweed Fucoidan in Cancer: Implications in Metastasis and Drug Resistance.Marine drugs · 2020Review
- Screening and identification of key biomarkers in alimentary tract cancers: A bioinformatic analysis.Cancer biomarkers : section A of Disease markers · 2020Article
- Marine Polysaccharides in Pharmaceutical Applications: Fucoidan and Chitosan as Key Players in the Drug Delivery Match Field.Marine drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidan, a sulfated polysaccharide present in marine brown seaweed, has been demonstrated to inhibit in vivo and in vitro growth of cells. The present study was conducted in HT‑29 human colon cancer cells cultured at a high density, and examined the potential underlying mechanisms by which fucoidan exerts its anti‑proliferative effects, which remain poorly understood. Fucoidan treatment of high‑density HT‑29 cells resulted in the inhibition of cell growth and increased apoptotic cell death. Flow cytometric analysis revealed that fucoidan treatment led to sub‑G1 phase cell cycle arrest. This was associated with decreased protein expression levels of Retinoblastoma protein and E2 factor protein. In conclusion, the results of the present study demonstrated that fucoidan possesses anticancer activity against high density HT‑29 cells by inhibiting cell growth and cell cycle progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.